Yuva Biosciences

What Yuva Biosciences does

Yuva Biosciences is a Birmingham, Alabama-based private biotech company founded in 2019 that operates at the intersection of mitochondrial science and AI-driven drug discovery. The company's core technology is the proprietary MitoNova AI platform, which is purpose-built to predict and validate biologically active compounds that improve mitochondrial health through iterative AI-biology feedback loops where computational predictions are tested on Yuva-designed assay systems and the experimental results are fed back to retrain the model. The platform is trained on years of proprietary in-house testing data with multi-dose, multi-timepoint outcomes not available in public datasets, creating a data flywheel advantage. Yuva's flagship commercial compound is Y100, a clinically proven cosmetic active ingredient that boosts mitochondrial function and reverses visible signs of aging, supported by 10+ patents, 5+ clinical studies, and 6+ years of research.

Yuva operates a B2B licensing business model, generating revenue through licensing royalties on its proprietary compounds. The company serves two primary customer segments: (1) consumer beauty and personal care brands, where Y100 is licensed for anti-aging skincare, hair regrowth, and wellness products via partnerships with BosleyMD (Revive+ hair serum, nationally launched February 2024) and Elevai Labs (S-Series Root Renewal System, launched December 2024); and (2) pharmaceutical and biotech companies, via a co-development partnership with NorthStrive Biosciences (a PMGC Holdings subsidiary) to identify small-molecule candidates for obesity, cardiometabolic disease, and muscle preservation in GLP-1 receptor agonist patients. In July 2026, Phase III validation of the NorthStrive program yielded four compounds demonstrating up to +50% ANT1 protein expression increases.

The company is led by Co-Founder and CEO Greg Schmergel (serial entrepreneur, former Ernst & Young Entrepreneur of the Year), Scientific Founder and CSO Dr. Keshav Singh (world authority in mitochondrial biology, 100+ publications), and Co-Founder and COO Saksham Narang, with Chief Data Scientist Jeb Linton (former IBM Watson Architecture Board co-chair) and Chief Strategy Advisor Shekhar Mitra (former P&G SVP of Global Innovation) supporting AI and commercial scaling. Yuva has raised $7.5 million in seed funding (February 2024) led by VentureSouth, with offices in Birmingham, New York City, and Boston.

Name

Yuva Biosciences

Legal name

Yuva Biosciences

Website

https://yuvabio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Yuva Biosciences is a Birmingham, Alabama-based biotech that uses its proprietary MitoNova AI platform to discover mitochondrial health compounds. It licenses its Y100 ingredient to consumer beauty brands like BosleyMD and partners with pharmaceutical companies like NorthStrive Biosciences for drug discovery in aging-related diseases.

Ownership category

akta.pro rank

Product category

AI-Driven Mitochondrial Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Mitochondrial health research
• AI drug discovery
• Cosmeceutical ingredients
• Compound licensing services
• Anti-aging biotechnology

Headquarters

HQ city

Birmingham

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: Yuva Biosciences licenses its proprietary compound Y100 to consumer product companies for use in skincare, haircare, and other cosmetic products. The company also licenses technology and compounds to pharmaceutical partners for drug development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Yuva Biosciences develops proprietary compounds and an AI discovery platform that target mitochondrial health. The MitoNova AI platform identifies biologically active compounds modulating mitochondrial function, and the company licenses its lead ingredient Y100 to consumer brands for skincare and haircare products, while also partnering with pharmaceutical companies on drug discovery for obesity and cardiometabolic diseases.

Product overview

Yuva Biosciences operates as a platform-plus-products company focused on AI-driven mitochondrial health. The core of the offering is the proprietary MitoNova™ AI Platform, which discovers compounds that improve mitochondrial health through an iterative AI-biology feedback loop. Key products include Y100™, a clinically proven cosmetic active ingredient licensed to consumer product brands, and compounds used in partner products such as Revive+ by BosleyMD for hair regrowth and the S-Series Root Renewal System developed with Elevai Skincare. The company also provides compound licensing services for skincare and haircare applications.

Differentiator

Problem solved

Functional benefit

Products and services

• MitoNova AI Platform Proprietary AI platform optimized for discovering compounds that improve mitochondrial health, using iterative AI-biology feedback loops to predict and validate biologically active compounds. Licensed to pharmaceutical and biotech partners for drug discovery.
• Y100 Cosmetic Active Ingredient Proprietary cosmetic active ingredient that reverses visible signs of aging by boosting mitochondrial health. Available for licensing to consumer brands for use in skincare and haircare products.
• AI-Powered Cardiometabolic and Obesity Therapy Discovery Co-development program leveraging MitoNova AI to identify and validate small-molecule candidates targeting mitochondrial health and muscle preservation for GLP-1 receptor agonist patients. Phase III validation identified four compounds with up to +50% ANT1 expression increases.

Quantifiable outcome

• +50% ANT1 protein expression increase in skeletal muscle cells (strongest candidate C2)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• NorthStrive BiosciencescoreStrategic or Co-development Partner · 10 April 2025Partnership to develop AI-powered therapies for obesity and cardiometabolic diseases. Yuva Biosciences provides its MitoNova AI platform to identify and validate small-molecule candidates targeting mitochondrial health and muscle preservation for GLP-1 receptor agonist patients. Phase III validation successfully identified four compounds (C1, C2, C3, C4) demonstrating dose-dependent ANT1 expression increases of up to +50%.
• BosleyMDcoreOEM/ Whitelabel/ Licensing Partner · 1 February 2024BosleyMD launched Revive+ hair serum incorporating Yuva Biosciences' Y100 compound. The product was described as 'One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years'. Product is sold nationally through BosleyMD channels.
• Elevai LabssecondaryOEM/ Whitelabel/ Licensing Partner · 29 November 2023Licensing agreement for Yuva Biosciences' exosome and mitochondrial technology for use in Elevai Skincare's S-Series Root Renewal System for hair and scalp health. Initial availability through select medical aesthetics partners in the United States.
• Southern ResearchsecondaryStrategic or Co-development PartnerYuva Biosciences received a Therapeutic Development Fund grant from Southern Research to address ovarian aging.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insilico Medicine: AI-driven drug discovery company with a heavy focus on aging, age-related diseases and longevity, applying generative chemistry and target identification to develop novel small molecules. Directly comparable to Yuva's MitoNova platform in combining generative AI with biological validation against aging indications.
• Recursion Pharmaceuticals: Operates one of the most prominent AI-enabled drug discovery platforms, using high-throughput biology and machine learning to identify novel therapeutics across multiple disease areas. Most directly comparable to Yuva as a competing AI-first biotech with platform economics.
• Schrödinger, Inc. Provides computational chemistry and physics-based software for molecular discovery, used both internally for drug programs and licensed to pharma partners. Comparable to Yuva as a computational discovery platform monetized through both partnerships and proprietary pipeline assets.
• Exscientia: Pioneer in AI-driven small molecule drug discovery, using generative AI to design candidates and partner with pharma for development. Closely mirrors Yuva's model of combining an AI platform with pharma co-development partnerships to advance small-molecule therapeutics.
• BioAge Labs: Clinical-stage biotech developing therapeutics that target the biology of aging, including metabolic and obesity-related indications. Highly comparable to Yuva on the disease-focus axis (aging, cardiometabolic, muscle biology) and on the data-driven discovery approach.

Broad incumbents

• Stealth BioTherapeutics: Late-stage biotech focused on mitochondrial-targeted therapeutics for diseases involving mitochondrial dysfunction. Comparable to Yuva's pharma pipeline as a mitochondria-focused drug developer, but at clinical/commercial stage rather than AI-discovery.
• MitoQ Limited: Commercial-stage company selling mitochondria-targeted supplements and skincare products globally. Comparable to Yuva's Y100 consumer licensing business as a mitochondrial health brand monetizing the same underlying biology through consumer channels.
• Elysium Health: Consumer longevity company developing and selling scientifically validated supplements (e.g., Basis) targeting cellular health and aging pathways. Comparable to Yuva's consumer/mitochondrial focus as an established brand in the longevity consumer category.

Emerging players

• Loyal for Dogs: Clinical-stage veterinary biotech developing drugs to extend dog lifespan by targeting metabolic and aging mechanisms, with FDA engagement. Comparable to Yuva as a fellow emerging player translating aging-biology science into regulated therapeutics.
• Arcaea (formerly Sundial Foods/Arcaea): Biotech company building biologically driven ingredients and products for the beauty and personal care industry. Comparable to Yuva's Y100 licensing model as a science-first entrant selling proprietary ingredients into prestige consumer brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/YuvaBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuva Biosciences